$10.02
0.212.14%
At Close: -
$10.02
00.00%
After Hours: Jul 5, 4:00 PM EDT
15 minutes delayed
Amicus Therapeutics
FOLDNASDAQ
want to know what
the Bulls & Bears Say?
Amicus Therapeutics (NASDAQ:FOLD) Stock, Analyst Ratings, Price Targets, Forecasts
Amicus Therapeutics Inc has a consensus price target of $15 based on the ratings of 25 analysis. The 3 most-recent analyst ratings were released by Wells Fargo, Guggenheim, and UBS on May 30, 2024, May 14, 2024, and May 10, 2024, respectively. With an average price target of $16.67 between Wells Fargo, Guggenheim, and UBS, there's an implied 66.33% upside for Amicus Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Wells Fargo
Guggenheim
UBS
Morgan Stanley
B of A Securities
1calculated from analyst ratings
Analyst Ratings for Amicus Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/30/2024 | Buy Now | 79.64% | Wells Fargo | — | → $18 | Initiates | → Overweight | Get Alert |
| 05/14/2024 | Buy Now | 29.74% | Guggenheim | Debjit Chattopadhyay | → $13 | Upgrade | Neutral → Buy | Get Alert |
| 05/10/2024 | Buy Now | 89.62% | UBS | Karl Chalabala | $20 → $19 | Maintains | Buy | Get Alert |
| 05/10/2024 | Buy Now | 89.62% | Morgan Stanley | Jeffrey Hung | $20 → $19 | Maintains | Overweight | Get Alert |
| 05/10/2024 | Buy Now | 29.74% | B of A Securities | Tazeen Ahmad | $14 → $13 | Maintains | Buy | Get Alert |
| 05/10/2024 | Buy Now | — | Needham | Gil Blum | — | Reiterates | → Hold | Get Alert |
| 03/18/2024 | Buy Now | 89.62% | JP Morgan | Anupam Rama | $21 → $19 | Maintains | Overweight | Get Alert |
| 02/29/2024 | Buy Now | 119.56% | Cantor Fitzgerald | Kristen Kluska | → $22 | Reiterates | Overweight → Overweight | Get Alert |
| 12/19/2023 | Buy Now | 99.6% | Morgan Stanley | Jeffrey Hung | $15 → $20 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 11/09/2023 | Buy Now | 49.7% | Morgan Stanley | Andrew Galler | $14 → $15 | Maintains | Equal-Weight | Get Alert |
| 10/10/2023 | Buy Now | 39.72% | Morgan Stanley | Andrew Galler | $15 → $14 | Maintains | Equal-Weight | Get Alert |
| 09/29/2023 | Buy Now | 89.62% | JP Morgan | Anupam Rama | $17 → $19 | Maintains | Overweight | Get Alert |
| 07/11/2023 | Buy Now | 49.7% | Morgan Stanley | Andrew Galler | $15 → $15 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
| 03/28/2023 | Buy Now | 69.66% | B of A Securities | Tazeen Ahmad | $16 → $17 | Maintains | Buy | Get Alert |
| 03/02/2023 | Buy Now | 69.66% | UBS | Karl Chalabala | $15 → $17 | Maintains | Buy | Get Alert |
| 03/02/2023 | Buy Now | 9.78% | Goldman Sachs | Salveen Richter | $10 → $11 | Maintains | Neutral | Get Alert |
| 01/18/2023 | Buy Now | 59.68% | BTIG | Yun Zhong | $14 → $16 | Maintains | Buy | Get Alert |
| 11/08/2022 | Buy Now | 49.7% | Morgan Stanley | Andrew Galler | $14 → $15 | Maintains | Equal-Weight | Get Alert |
| 09/09/2022 | Buy Now | 39.72% | Morgan Stanley | Andrew Galler | → $14 | Initiates | → Equal-Weight | Get Alert |
| 02/24/2022 | Buy Now | 39.72% | SVB Leerink | Joseph Schwartz | $16 → $14 | Maintains | Outperform | Get Alert |
| 01/14/2022 | Buy Now | 59.68% | SVB Leerink | Joseph Schwartz | $12 → $16 | Upgrade | Market Perform → Outperform | Get Alert |
| 01/13/2022 | Buy Now | 49.7% | Cantor Fitzgerald | Kristen Kluska | $16 → $15 | Maintains | Overweight | Get Alert |
| 11/15/2021 | Buy Now | 59.68% | Stifel | Dae Gon Ha | — | Upgrade | Hold → Buy | Get Alert |
| 09/30/2021 | Buy Now | 59.68% | JP Morgan | Anupam Rama | — | Upgrade | Neutral → Overweight | Get Alert |
| 09/30/2021 | Buy Now | 19.76% | SVB Leerink | Joseph Schwartz | — | Maintains | Market Perform | Get Alert |
FAQ
What is the target price for Amicus Therapeutics (FOLD) stock?
The latest price target for Amicus Therapeutics (NASDAQ:FOLD) was reported by Wells Fargo on May 30, 2024. The analyst firm set a price target for $18.00 expecting FOLD to rise to within 12 months (a possible 79.64% upside). 13 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Amicus Therapeutics (FOLD)?
The latest analyst rating for Amicus Therapeutics (NASDAQ:FOLD) was provided by Wells Fargo, and Amicus Therapeutics initiated their overweight rating.
When was the last upgrade for Amicus Therapeutics (FOLD)?
The last upgrade for Amicus Therapeutics Inc happened on May 14, 2024 when Guggenheim raised their price target to $13. Guggenheim previously had a neutral for Amicus Therapeutics Inc.
When was the last downgrade for Amicus Therapeutics (FOLD)?
There is no last downgrade for Amicus Therapeutics.
When is the next analyst rating going to be posted or updated for Amicus Therapeutics (FOLD)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Amicus Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Amicus Therapeutics was filed on May 30, 2024 so you should expect the next rating to be made available sometime around May 30, 2025.
Is the Analyst Rating Amicus Therapeutics (FOLD) correct?
While ratings are subjective and will change, the latest Amicus Therapeutics (FOLD) rating was a initiated with a price target of $0.00 to $18.00. The current price Amicus Therapeutics (FOLD) is trading at is $10.02, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.